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ÖZET:
Şizofreni hastalarında ajitasyonun tedavi-
sinde uzamış salınımlı ketiyapin fumarat’ın 
etkinlik ve güvenliği: 3 haftalık, açık etiketli 
bir çalışma
Amaç: Bu çalışmada, akut şizofreni  hastalarında ajitas-
yonun tedavisinde uzamış salınımlı ketiyapin fumarat’ın 
(XR) etkinliğini değerlendirmek amaçlandı.
Yöntem: Üç haftalık açık etiketli olarak tasarlanan bu 
çalışmaya yatan veya ayaktan şizofreni hastaları dahil 
edildi. Ketiyapin XR 1. gün 300 mg, 2. gün 600 mg ve 3. 
günden itibaren araştırmacının takdirine göre 400-800 
mg/gün dozunda uygulandı. Birincil sonlanım noktası 
olarak bazal Pozitif ve Negatif Semptom Skalasının 
Eksite Bileşeni (PANSS-EC) puanındaki değişim alın-
dı. İkincil sonlanım noktası olarak bazal PANSS-Pozitif, 
PANSS-Negatif, PANSS-Genel Psikopatoloji (PANSS-G) 
alt ölçek skorları ile toplam PANSS skoru, PANSS agres-
yon, hostilite ve depresyon skorları, CGI-Hastalık Şiddeti 
(CGI-S) ve  CGI-İyileşme (CGI-I) puanlarındaki değişim 
esas alındı. Tolerabilitenin değerlendirmesi amacıyla 
bildirilen yan etkiler (YE), Simpson-Angus Ölçeği (SAÖ), 
Barnes Akatizi Derecelendirme Ölçeği (BADÖ), labora-
tuvar ölçümleri ve elektrokardiyogram (EKG) kullanıldı.  
Sonuç: Çalışmaya alınan 40 hastadan 35’i çalışmayı 
tamamlamıştır. Yirmi birinci günde birincil ve ikincil 
sonlanım noktası değerlendirmelerinde başlangıca 
göre istatistiksel olarak anlamlı değişme gözlendi. YE 
insidansı düşüktü ve tüm yan etkiler hafif orta şid-
detteydi. SAÖ ve BADÖ ile yapılan değerlendirmeye 
göre hiç ekstrapiramidal semptom (EPS) saptanmadı 
ve tedavi iyi tolere edildi. Bir hastada psikozun relapsı 
nedeniyle hospitalizasyon gerekti, ancak bu durumun 
tedaviyle ilişkisi olmadığı değerlendirildi.
Sonuç: Günde tek doz ketiyapin fumarat akut şizofreni 
semptomlarının ve ajitasyonun azaltılmasında etkilidir. 
Bu çalışmada, hızlı doz titrasyonuna rağmen tedavi 
genel olarak iyi tolere edilmiştir.   
Anahtar sözcükler: Antipsikotik ajanlar, şizofreni, psi-
komotor ajitasyon, tedavi
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ABS TRACT:
A 3-week, open label study to evaluate the 
efficacy and safety of extended release 
quetiapine fumarate in the treatment of 
agitation in patients with schizophrenia
Objective: To evaluate the efficacy of extended-release 
quetiapine fumarate (XR) monotherapy once daily, 
in the treatment of patients with acute episodes of 
schizophrenia and agitation. 
Method: Our study was a 3-week open-label study 
conducted in adult in- or outpatients with schizophrenia. 
Quetiapine XR was initiated at 300 mg on day 1, 600 
mg on day 2, and 400-800 mg (at the investigator’s 
discretion) on day 3 and onwards. The primary endpoint 
was the change from baseline in the Positive and 
Negative Syndrome Scale Excited Component (PANSS-
EC) score. Secondary endpoints included change from 
baseline in PANSS-Positive, PANSS-Negative, PANSS-
General Psychopathological (PANSS-G) subscale scores, 
total PANSS score, PANSS aggression, hostility and 
depression cluster scores, CGI-Severity of illness (CGI-
S) and the absolute CGI-Improvement (CGI-I) scales. 
Tolerability was assessed based on reported adverse 
events (AEs), the Simpson-Angus Scale (SAS) and 
Barnes Akathisia Rating Scale (BARS) scores, laboratory 
measurements and electrocardiograms (ECGs).
Results: Of 40 patients enrolled, 35 completed the 
study. At day 21, statistically significant improvements 
versus baseline were seen for the primary and all 
secondary endpoints assessed. The incidence of AEs 
was low, and all were mild to moderate in severity. No 
extrapyramidal symptoms (EPS) as measured by the SAS 
and BARS were reported, indicating that the treatment 
was well tolerated. Hospitalization was required in one 
out-patient due to a relapse of psychosis, but was not 
considered to be treatment related.
Conclusion: Once-daily quetiapine fumarate XR (400-
800 mg/day) was effective in reducing agitation and 
a broad range of symptoms in acute schizophrenia. 
Treatment, including rapid dose escalation, was 
generally well tolerated in this study.
Key words: Antipsychotic agents, quetiapine, 
schizophrenia, psychomotor agitation, treatment
Bulletin of Clinical Psychopharmacology 2013;23(1):14-23
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 INTRODUCTION
 Immediate release quetiapine (IR) is an atypical 
antipsychotic used as first-line treatment for patients 
with schizophrenia. It is effective against positive 
and negative symptoms whilst exhibiting a good 
tolerability profile in long term treatment, with 
placebo-like incidence of extrapyramidal symptoms 
(EPS), e.g. akathisia, parkinsonism or dystonia, and 
is associated with minimal weight gain (1). It is 
usually administered twice daily and requires dose 
titration over 4 days to reach the target therapeutic 
dose (Seroquel XR® Prescribing Information).
 Extended release quetiapine fumarate 
(quetiapine XR) is a new formulation of quetiapine, 
developed to provide sustained exposure to the drug 
when administered once daily, at therapeutically 
effective doses reached from day 2 (2). 
 In Malaysia, many schizophrenic patients still 
delay seeking treatment (3). Most families opt for 
alternative treatment methods, such as traditional 
healers (4). Only when the person becomes 
aggressive will he/she be brought in to psychiatric 
services. Hence, most patients will require an 
effective treatment method to control their agitation 
upon admission. Furthermore, in patients with 
psychotic disorders, compliance is especially 
important and problematic and provides a strong 
rationale for reducing the frequency of 
administration and simplifying the dose-titration 
regimen (5-7).
 A recent study has demonstrated the safety and 
tolerability of quetiapine XR once daily (400-800mg/
day) versus placebo in patients with acute 
schizophrenia (2). Treatment including rapid dose 
escalation was well tolerated. The improvement, 
expressed as the change from baseline in the Positive 
and Negative Syndrome Scale (PANSS) total score 
and Clinical Global Impression-Improvement 
(CGI-I) response rates, was significantly larger than 
that observed for placebo. Evidence from several 
small studies has suggested that a more rapid dose 
initiation, allowing for a dose of up to 800 mg/day 
by day 4, might be a generally well tolerated and 
effective treatment for patients with acute 
schizophrenia (8-10). 
 Patients with schizophrenia accompanied with 
acute psychotic symptoms often display signs of 
aggression and hostility, which can lead to a 
challenge for psychiatrists in terms of treatment 
and diagnosis. One of the preferential aims of 
treatment in schizophrenia is to rapidly resolve 
psychotic symptoms that often manifest as 
aggression and hostility to prevent harm to the 
patient and to others. On many occasions, 
practitioners have resorted to polypharmacy in an 
attempt to control these symptoms. Several studies 
have shown the efficacy of quetiapine in the acute 
setting (11-15) with significant improvements in 
aggressive symptoms observed within 24h in a 
naturalistic uncontrolled trial (9). 
 The objective of this present study was to assess 
the effectiveness of quetiapine fumarate XR in 
controlling agitation for patients with acute 
schizophrenia. Safety and tolerability were also 
evaluated. 
 PATIENTS AND METHODS
 Study Design
 This was a 3-week open-label study (Study 
D1444C00146, ClinicalTrials.gov Identifier: 
NCT00954122), conducted at 2 centers in Johor and 
Kuala Lumpur, respectively, from September 2009 to 
April 2010. There were 7 investigators in total from 
both sites, all of whom were qualified psychiatrists. 
They were not blinded to the study objectives. All of 
them had received the required training during the 
investigators’ meeting and all of the investigators 
demonstrated high inter-rater reliability.
 The study was performed in accordance with the 
Declaration of Helsinki and the International 
Conference on Harmonization and Good Clinical 
Practice guidelines. Written informed consent was 
obtained from all patients, and approvals of the local 
institutional review boards/ethics committees were 
obtained from each study center. All patients were 
equally familiar with the language in which the study 
was conducted and the informed consent forms 
were available in the 3 main languages in Malaysia 
namely Bahasa Malaysia, English and Mandarin.
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 Patients
 The study included male and female patients, 
aged 18-65 years, with a Diagnostic and Statistical 
Manual of Mental Disorders-IV (DSM-IV) diagnosis 
of schizophrenia (1st episode/relapse). Key inclusion 
criteria were a PANSS total score of ≥ 75; a PANSS-
Excited Component (PANSS-EC) score of ≥ 14; a 
severity score of at least 4 on at least one of the five 
PANSS-EC items (P4 – Excitement, P7- Hostility, G4 
– Tension, G8 – Uncooperativeness, or G14 – Poor 
Impulse Control) and a Clinical Global Impression 
(CGI) score ≥4. The patients were recruited from the 
acute inpatient wards or from the outpatient clinics 
after they were screened thoroughly according to 
the inclusion/exclusion criteria stated in the study 
protocol. 
 Key exclusion criteria included any other Axis I 
diagnosis (DSM-IV) not defined in the inclusion 
criteria; patients who posed an imminent risk of 
suicide or danger to self or others (in the opinion of 
the investigator); pregnancy or lactation; unstable 
or inadequately treated medical illness (e.g. 
congestive heart failure, angina pectoris, 
hypertension); substance abuse or alcohol 
dependence at enrolment as defined by DSM-IV 
criteria; unstable diabetes mellitus; an absolute 
neutrophil count (ANC) of ≤ 1.5 x 109 per liter; 
abnormal ECG or participation in another drug trial 
within 4 weeks prior to enrolment.
 In order to exclude treatment-resistant patients, 
the following groups were also excluded: patients 
with a known intolerance or lack of response to 
quetiapine fumarate as judged by the investigator; 
patients with a known lack of response to 2 or more 
antipsychotics with adequate doses given for at 
least 4 weeks; patients who required clozapine 
treatment for symptom control and patients treated 
with clozapine within 1 month prior to enrolment. 
The patients were hospitalized if required for 
treatment and assessment based on the 
investigator’s judgment. If the patient was 
hospitalized, he/she could be discharged from the 
hospital if the investigator believed that it was 
clinically appropriate, and the patient could 
reasonably be expected to continue in the study on 
an outpatient basis.
 Treatment
 Eligible patients enrolled on day 1 were treated 
with quetiapine fumarate XR for 21 days. Quetiapine 
fumarate XR was administered orally, once daily. 
The initial dose was given when the patient entered 
treatment; morning doses were preferred to give 
maximum drug concentration during daytime. The 
initial dose was 300 mg; the dose on day 2 was 600 
mg; from Day 3 to Day 21, the dose of quetiapine 
fumarate XR could be adjusted to 400 mg/day, 600 
mg/day, or 800 mg/day (Figure 1) at the investigator’s 
discretion based on the subject’s clinical response 
and tolerance. 
 Lorazepam could be administered to treat 
agitation and anxiety, up to 6 mg/day, but was not 
given in the morning before scheduled assessments. 
Zolpidem tartrate (up 10 mg/day), zaleplon (up to 20 
mg/day) and zopiclone (up to 7.5 mg/day) were 
permitted to treat sleep disturbances throughout the 
study; all other sleep medications were prohibited. 
Antidepressants (serotonin-norepinephrine 
reuptake inhibitors, selective serotonin reuptake 
inhibitors), mood stabilizers lithium and divalproex 
were allowed if the patient had been on a stable dose 
of the medication for at least 14 days before 
Figure 1: Flow chart of study design
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enrolment. Anticholinergics could be used to treat 
emergent EPS but prophylactic use was not permitted.
 The introduction of antidepressants, anxiolytics, 
mood stabilizers, hypnotics, sedative medications 
or other antipsychotic or psychoactive drugs during 
the study was prohibited, and was discontinued at 
least 1 week before day 1. Use of drugs that induce 
or inhibit the hepatic drug metabolizing cytochrome 
P450 3A4 enzymes were also not permitted from 14 
days prior to day 1 until the end of the treatment 
period. Depot and long-lasting antipsychotics must 
have been stopped within at least two and preferably 
three dosing intervals prior to day 1 and were 
prohibited during the treatment period.
 Study Objectives
 Primary Objective
 The primary objective was to evaluate the 
efficacy of quetiapine fumarate XR monotherapy, 
once daily, in the treatment of agitation in patients 
with acute episodes of schizophrenia. The primary 
outcome variable was the change from baseline in 
the PANSS-Excited Component (PANSS-EC) score.
 Secondary objectives
 Efficacy
 The secondary efficacy objectives were to 
evaluate (i) the efficacy of quetiapine fumarate XR 
in reducing the positive, negative and general 
psychopathological symptoms, and aggression, 
hostility, and depression in the treatment of acute 
schizophrenia; (ii) the efficacy of quetiapine 
fumarate XR in improving the overall clinical status 
of patients with acute schizophrenia and (iii) the 
safety and tolerability of quetiapine fumarate XR in 
the treatment of patients with acute schizophrenia. 
The variables used to evaluate the secondary 
outcomes were: (i) change from baseline in the 
PANSS-Positive (PANSS-P), PANSS-Negative 
(PANSS-N), and PANSS-General Psychopathological 
(PANSS-G) subscale scores at the end of treatment; 
(ii) change from baseline in total the PANSS score; 
(iii) change from baseline in the PANSS aggression, 
hostility and depression clusters scores at the end of 
treatment; and (iv) change from baseline in CGI-
Severity of illness (CGI-S) and absolute CGI-
Improvement (CGI-I) scales.
 Safety And Tolerability
 The tolerability of quetiapine XR was assessed by 
monitoring the number and severity of adverse 
events (AEs) and withdrawals throughout the study 
period. Laboratory measurements including 
hematology and clinical chemistry, as well as 
electrocardiograms were performed at enrolment 
and week 12. Vital signs (blood pressure and pulse 
rate) and changes in body weight were assessed at 
every visit until the end of the study.
 Assessments
 Following enrolment (Visit 1), study visits were 
scheduled for days 1, 2, 4, 7, 14 and 21 (Table 1). The 
first dose of study medication was dispensed on Visit 
1 or Visit 2, depending on whether assessment results 
could be obtained on the day of enrolment (Visit 1). 
 Statistical Analysis
 Due to the exploratory nature of this study, the 
sample size was not based on any statistical 
calculations.
 Data analyses were based on 2 patient populations: 
intention-to-treat (ITT) and safety. The ITT population 
consisted of all patients who were given quetiapine 
fumarate XR and who had a baseline value and at 
least 1 set of valid post-baseline PANSS assessments. 
The safety population consisted of all patients given 
at least one dose of the study medication.
 The changes in PANSS total and subscales scores 
were analyzed using the T-test under the null 
hypothesis of no change in the scores from baseline. 
The mean value and a two-sided 95% confidence 
interval (CI) were calculated for each change. 
 The CGI-S assessment was based upon the 
subject’s symptoms during the previous week.
 The T-test was used to analyze the significant of 
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the change in the CGI-S score from baseline, with 
reference to the null hypothesis of no change in the 
CGI-S score from baseline.
 A paired T-test was used to compare the pre and 
post CGI-I score at each visit under the null 
hypothesis that the mean scores of the pre and post 
CGI-I scales are even. 
 RESULTS
 Patients
 In total, 40 patients were enrolled. Of these, 35 
(87.5%) were eligible and proceeded to receive the 
study medication, and these subjects comprised 
both the ITT and safety populations. Out of the 5 
patients who failed screening and were excluded 
from the study, 3 patients did not fulfill the eligibility 
criteria (1 had diabetes and 2 had positive urine 
tests for cannabis), while 2 patients experienced 
AEs (1 with abnormal ECG with a corrected QT 
interval of 541 milliseconds, and 1 with high blood 
pressure and elevated creatine kinase). 
 Out of the 35 patients receiving the study 
medication, 7 (17.5%) discontinued treatment early 
due to voluntary discontinuation (n=5), AE (n=1) 
and for safety reason (n=1). The AE reported was 
hospitalization due to relapse of psychosis, while 
the safety reason was worsening of psychotic 
symptoms in the patient (Table 2). Twenty-eight 
patients completed the study. All patients who 
withdrew early from the study returned on Day 21 to 
have assessments performed at the end of the study 
period. There were more male than female patients 
in the study (24 vs. 11); Malay and Chinese patients 
accounted for more than 70% of the subject 
population. The other 30% of the subjects were 
made up of Indians and 1 Pakistani patient. The 
mean age of the patients was 38.3±11 (SD) years.
 Based on the DSM-IV Diagnostic Criteria, the 
predominant type of schizophrenia among the 
patients was paranoid schizophrenia (71.4%), 
followed by undifferentiated schizophrenia (17.1%) 
and disorganized schizophrenia (11.4%). Most of 
the patients (n=27) had a psychiatric history. The 
number of lifetime hospitalization for schizophrenia 
among the patients ranged from 0 to 31 times, with 
an average of 3 (±5.2 SD). The mean age at which the 
patients first received treatment for psychiatric 
illness was 29.3 (±6.8 SD) years.
 Four patients (11.4%) had a medical history; 
three had been treated in the past for childhood 
asthma, tuberculosis and hepatitis B (carrier), 
respectively, and one was receiving current 
Tab le 1: Study plan
Visit 1 2 3 4 5 6 7a
Visit Description Enrolment + Treatment     Final
 Treatmentb      visit
Day < Up to – 1 day 1 2 4 7 14 21
Visit Window (± No. Days)     ± 1 ± 3 ± 3
Informed consent X      
Medical history X      
Inclusion/Exclusion criteria X X     
Physical examination X      X
Vital signs/Weight X X X X X X X
ECG X      X
Clinical chemistry/Haematology X      X
Urinalysis/Pregnancy X      
PANSS X X X X X X X
CGI-S and CGI-I Xc X X X X X X
SAS  X X X X X X
BARS  X X X X X X
Dispense study medication  X X X X X 
Concomitant medication X X X X X X X
Adverse events X X X X X X X
a Day 21 assessments was performed at the end of treatment for all patients including those who withdrew early.
b Study medication was started if result could be obtained on the same day as enrolment, visits 1 & 2 combined visit.
c At visit 1, only CGI-S was performed.
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medication for the condition of periodic paralysis. 
Two patients (5.7%) had a surgical history in the 
past but were not currently taking medication. The 
demographic and key baseline characteristics, 
including baseline measurements of the PANSS 
scores, CGI scores and EPS symptom scores, of the 
study subjects are summarized in Table 3.
 A total of 30 (85.7%) patients received medication 
prior to the study. A majority of them (n=29, 82.9%) 
were on psycholeptic treatment. The most common 
psycholeptics used were benzodiazepine derivatives 
Tab le 4: Concomitant Medications Patients Received During 
the Study
  All Patients
  (N=35)
Any concomitant treatment 22 (62.9%)
Type of medication 
Magnesium compounds (for acid-related disorder) 1 (2.9%)
Propulsives (for functional gastrointestinal disorder) 1 (2.9%)
Contact laxatives 1 (2.9%)
Potassium supplement 1 (2.9%)
Tertiary amines (for anti-Parkinson) 1 (2.9%)
Psycholeptics 21 (60%)
Butyrophenone derivatives 2 (5.7%)
Diazepines, oxazepines, thiazepines and oxepines 1 (2.9%)
Other antipsychotics 3 (8.6%)
Benzodiazepine derivatives 20 (57.1%)
Benzodiazepine- related drugs 1 (2.9%)
Substituted alkylamines (antihistamines for systemic use) 1 (2.9%)
Tab le 3: Demographic and baseline characteristic of subjects 
(ITT population)
Population Subjects (N=35)
Demographic characteristics 
Sex, n (%)
 Male 24 (68.6%)
 Female 11 (31.4%)
 Age, years (SD) 38.3 (11) 
Race, n (%)
 Malay 12 (34.3%)
 Chinese 13 (37.1%)
 Indian 9 (25.7%)
 Others (Pakistani) 1 (2.9%)
Height, cm (SD)  165.1 (6.9)
Baseline characteristics
Subjects with:
Medical history 4 (11.4%)
Surgical history 2 (5.7%)
Psychiatric history 27 (77.1%)
Subjects with schizophrenia (based on DSM-IV Diagnosis
criteria)
Disorganized type 4 (11.4%)
Paranoid type 25 (71.4%)
Undifferentiated type 6 (17.1%)
Baseline efficacy measurements, mean (SD)
PANSS-EC score 17.8 (2.7)
PANSS-P score 26.6 (4)
PANSS-N score 25 (5.4)
PANNS-General psychopathological score 51.3 (7.6)
PANSS total score 110.8 (15.7)
CGI-S 4.6 (0.5)
CGI-I 3.9 (0.4)
Baseline EPS symptoms
SAS score 0
BARS score 0.1 (0.5)
Baseline values for efficacy measurements and SAS and BARS scores were values 
at visit 2.
Table 2: Disposition of patients
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(n=18, 51.4%), followed by other antipsychotics 
(n=16, 45.7%) and butyrophenone derivatives 
(n=12, 34.3%).
 A total of 22 (62.9%) patients received 
concomitant therapies during the study. A majority 
of them (n=21, 60.0%) were given concomitant 
psycholeptic treatment. The most common class of 
psycholeptic used was benzodiazepine derivatives 
(n=20, 57.1%). All concomitant medications patients 
received during the study are shown in Table 4. 
 Efficacy
 Efficacy analyses were based on the ITT population.
 Primary Efficacy Variable
 The primary variable was the change from 
baseline in PANSS-EC score to the end of treatment 
(day 21) where baseline was defined as the day the 
subject first received study medication (day 1, Visit 
2). Results showed that there was a steady decline in 
the mean PANSS-EC score over the course of the 
study, with a mean reduction of 7.5±4 points from 
baseline at day 21 (Table 4), thus indicating a 
statistically significant improvement ( p<0.001) in 
patients after receiving quetiapine fumarate XR.
 Secondary Efficacy Variables
 Results showed that there were reductions 
across the various PANSS subscales scores over 
the 3-week study period, indicating treatment 
with quetiapine fumarate XR led to improvement 
in the overall clinical status in patients with acute 
schizophrenia. Changes from baseline at each 
visit were statistically significant (p<0.001) for all 
the PANSS subscale variables and were evident 
from Visit 3 onwards up till the end of the study 
(Visit 7). 
 Table 5 shows the mean reduction from baseline 
for both primary and secondary efficacy variables.
 Safety and Tolerability
 Safety evaluation was performed in the safety 
population.
Tab le 5: Primary and secondary efficacy variables - Changes from baseline at Day 21*
Variables Mean±SD 95% Confidence interval T-test
Primary efficacy
 PANSS-EC -7.5±4 -8.842,-6.072 p<0.001
Secondary efficacy
 PANSS-P -9.3±5.5 -11.192,-7.379 p<0.001
 PANSS-N -5.7±4.9 -7.336,-3.979 p<0.001
 PANSS-G -15.2±10.5 -18.853,-11.605 p<0.001
 PANSS total -33.2±21.3 -40.502,-25.841 p<0.001
 Aggression & hostility cluster score -5.6±3.3 -6.705,-4.437 p<0.001
 Depression cluster score -3.1±2.5  -3.957,-2.214 p<0.001
CGI-S -1.2 ±0.9 -1.541,-0.916 p<0.001
 
  Baseline score±SD Day 21 score±SD Paired T-test
CGI-I 3.9±0.4 2.4±1.2¥ p<0.001
Tab le 6: Number (%) of Patients reporting Adverse Events – 
Safety Population
  All Subjects
  (N=35)
Study exposure, mean (days) 16.7 (9,21)
Number of patients experienced AE, n (%) 3 (8.6%) 
ADVERSE EVENT, n (%) 5 (14.3%) 
Dry mouth1 1 (2.9%)
Sedation1 1 (2.9%)
Vomiting2 1 (2.9%)
Hospitalization 1 (2.9%)
Gastritis2 1 (2.9%)
MAX INTENSITY, n (%) 5 (14.3%)
2 - Moderate: Discomfort sufficient to cause
interference with normal activities 3 (8.6%)
1 - Mild: Awareness of sign or symptom,
but easily tolerated 2 (5.7%)
1Dry mouth and sedation occurring in one patient.
2Vomiting and gastritis occurring in one patient.
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 Adverse Events
 Quetiapine fumarate XR was generally well 
tolerated during the study. Adverse events were 
reported in 3 (8.6%) patients in the safety population 
during the study period, after 16 days of study 
exposure. All AEs were mild to moderate in intensity 
(Table 6).
 The reported AEs were dry mouth, sedation, 
vomit ing,  gastr i t is  and hospital izat ion. 
Hospitalization due to relapse of psychosis occurred 
in one patient after 9 days of study exposure, and 
was considered as a serious AE that led to the 
patient’s early withdrawal from the treatment. Even 
though the patient was compliant with the study 
drug, the reason for the relapse was attributed to 
unresolved psychosocial stressors to which that the 
particular subject was exposed. Only dry mouth and 
sedation were judged by the investigators to be 
treatment-related. No deaths occurred during the 
study period.
 Laboratory Evaluations and Vital Signs
 The laboratory  evaluat ions  included 
hematological parameters (i.e. red blood cells, white 
blood cells, hemoglobin, platelets, hematocrit and 
neutrophils) and clinical chemistry parameters (i.e. 
HbA1c, glucose, prolactin, triglycerides, cholesterol, 
low-density lipoprotein cholesterol and high-
density lipoprotein cholesterol). Vital signs 
measured were weight, pulse, systolic blood 
pressure and diastolic blood pressure; ECGs were 
examined. 
 Overall, there were no individual clinically 
important abnormalities observed in the various 
safety evaluation parameters among the patients. 
Mean changes in the laboratory parameters at the 
end of the treatment were small and statistically 
and clinically insignificant, except for the levels of 
prolactin (-444.4±835.7 uIU/ml; p=0.005), 
triglycerides (0.4±0.9 mmol/L, p=0.008) and 
cholesterol (0.3±0.8 mmol/L; p=0.03). These 
changes were not considered by the investigators to 
be clinically important.
 There were no significant changes in the 
hematology parameters, ECG and vital signs. There 
was, however, a small but statistically significant 
1.1±1.8 kg increase in body weight observed from 
baseline to day 21. There were no significant changes 
observed in EPS over time. 
 DISCUSSION
 The aim of this 3-week, open label, single-arm 
study was to evaluate the efficacy in agitation and 
safety of quetiapine fumarate XR monotherapy, 
given once-daily, in treating patients with acute 
schizophrenia. Results from this study have 
indicated that once-daily quetiapine fumarate XR 
(400 mg, 600 mg, and 800 mg) was effective for the 
management of agitation in acute schizophrenia.
 In our study, the inclusion criteria for PANSS-EC 
was a score of >14. The mean baseline PANSS-EC 
score was 17.8, which was higher than that set for 
inclusion, indicating that the patients enrolled into 
this study had high scores of agitation at baseline. 
The reduction of 7.5 points in PANSS-EC score from 
baseline in this study was statistically significant, 
suggesting that the once-daily quetiapine fumarate 
XR used was effective in treating agitation in 
schizophrenia.
 Our result is in line with that reported for the 
benefits of quetiapine in a post-hoc analysis by 
Chengappa et al. (2003) (14). Their study has 
suggested that quetiapine treatment had effects on 
agitation, as assessed by the Brief Psychiatric Rating 
Scale, that were independent of improvements in 
the overall psychology.
 The CGI inclusion criteria for this study was set 
at >4, meaning that patients in our study were all at 
least moderately ill. A total PANSS score of 110.8 at 
baseline also showed that they had high scores for 
overall psychotic symptoms. The efficacy of once-
daily quetiapine fumarate XR in this patient 
population was supported by the statistically 
significant improvement observed in the secondary 
efficacy variables, i.e. PANSS-P, PANSS-N and 
PANSS-G subscales, total PANSS, as well as PANSS 
aggression, hostility and depression clusters. 
Significant improvement was also noted in the 
CGI-I and CGI-S scales. These results suggest that 
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quetiapine fumarate XR was effective against a 
broad range of symptoms in schizophrenia.
 Quetiapine fumarate XR was generally well 
tolerated, in agreement with the good tolerability 
profile reported in other studies (2,16). The 
incidence of AEs and serious AEs was low, with most 
of the incidences mild to moderate in intensity. Only 
dry mouth and sedation were considered to be 
treatment related. The effect of treatment on EPS, 
prolactin, glucose parameters and lipids is 
consistent with the results of randomized, placebo-
controlled studies of quetiapine IR. 
 No incidence of EPS was reported during the 
study; most patients showed no change in SAS and 
BARS scores. This was consistent with the known 
tolerability profile of quetiapine IR. The study 
withdrawal rate due to AE was low—one patient 
discontinued treatment due to hospitalization for 
relapse of psychosis, but this was not considered to 
be treatment-related. This indicated that the rapid 
initiation of quetiapine fumarate XR, reaching 600 
mg by day 2 and possibly 800 mg by day 3, in this 
patient population was both efficacious and 
generally well tolerated.
 The use of concomitant medications is standard 
in clinical practice for patients with severe agitation. 
Our study tried to mimic normal clinical practice by 
allowing the usage of benzodiazepines. Furthermore, 
the patients that were recruited for the study had 
moderate to severe illness at baseline (PANSS total 
score of 110 and CGI score of 4.6). However, the 
usage of benzodiazepines might have an impact on 
the results, and this was one of the limitations of this 
study.
 As illustrated in Table 4, 60% of the subjects 
received psycholeptics as concomitant medication. 
These included the antipsychotics they received 
before rapid titration of quetiapine was commenced. 
This was not a violation of the protocol since they 
received these medications prior to day 1, but after 
informed consent was obtained. Hence, they were 
recorded as ‘concomitant medications’. Similarly, it 
was noted that butyrophenone derivatives were 
received by 2 subjects, where both of them received 
an injection of intramuscular haloperidol, to control 
agitation, prior to day 1.
 The design of our study might also be limited by 
the absence of a control arm, the small sample size 
and the short study duration. These limitations may 
have introduced bias associated with the non-
comparative design and not provided information 
on the magnitude of any non-treatment-related 
response to the intervention. However, the efficacy 
of quetiapine XR has been earlier established in a 
placebo-controlled study (2) and an open-label 
study (16) and our study further supported the 
reported favorable efficacy and safety profile of 
quetiapine XR in the treatment of acute 
schizophrenia.
 Non-compliance is a major issue in patients with 
schizophrenia, and has been associated with 
treatment failure, relapse, and serious consequences, 
such as hospitalization or suicide (5-7). Side effects 
of treatment and the complexity of dosing regimens 
are some of the factors that can affect patients’ 
adherence to a treatment (17,19), thus providing a 
strong rationale for reduced administration 
frequency and a simplified dose-escalation regimen.
 The simplified dose-escalation regimen used in 
this study allowed physicians to administer 
quetiapine once-daily to reach an effective dose 
earlier, since patients with acute schizophrenia 
require a more rapid resolution of their symptoms. 
The good tolerability profile of quetiapine fumarate 
XR made it a more acceptable treatment choice for 
patients, encouraging patient adherence, a 
significant factor in improving long-term prognosis. 
 CONCLUSION
 The efficacy of quetiapine fumarate XR in 
reducing agitation as well as a broad range of 
symptom domains in acute schizophrenia was 
evident in this study, as reflected in the primary and 
secondary efficacy variables measured. The drug 
was generally well tolerated using rapid dose 
escalation (300 mg on day 1, 600 mg on day 2, and 
400-800 mg on day 3) in patients with acute 
schizophrenia treated for a period of up to 3 weeks. 
To better demonstrate the efficacy of quetiapine 
fumarate XR for this indication, further research 
should be considered to enhance our findings. 
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